Advent Life Sciences — 2019 Investments
1 investments dated 2019 · listed companies and verified rows first · show all
Genocea BiosciencesFeb 2019SEC filingmedium confidence
Uses a T-cell antigen discovery platform to develop vaccines for oncology and infectious disease.
BiotechCambridge, US
Narinder Singh(Executive Officer)Derek Meisner(Executive Officer)Michael Alfieri(Executive Officer)Jessica Flechtner(Executive Officer)Girish Aakalu(Executive Officer)Thomas Davis(Executive Officer)
Board seatKatrine Bosley· per SEC Form D · $15M raise · filed Feb 2019
Co-investorsCycad Group LLCLux CapitalMC Healthcare VenturesNew Enterprise Associates (NEA)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.